Qiagen N.V. operates in the Biological products exc. diagnostic sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Qiagen N.V. with three other
pharmaceutical manufacturers in Europe:
sales of 1.15 billion Euro [US$1.34 billion]
of which 84%
Richter Gedeon Vegyeszeti Gyar Nyilvanosan Mukodo Reszvenytarsasag
(389.69 billion Hungarian Forints [US$1.49 billion]
of which 81%
was Pharmaceutical Manufacturing and Sale), and
Krka DD Novo Mesto
based in Slovenia
(1.17 billion Euro [US$1.37 billion]
of which 63%
was European Union).
Qiagen N.V. reported sales of 1.21 billion Euro (US$1.41 billion)
December of 2016.
increase of 4.4%
versus 2015, when the company's sales were 1.16 billion Euro.
Sales at Qiagen N.V. have increased during each of the previous five years
(and since 2011, sales have increased a total of 45%).
Sales of Consumables and Related Revenues saw an increase
4.6% in 2016, from
1.01 billion Euro to 1.06 billion Euro.